QuickChek – April 12, 2021



enCore Energy Corp Hosting Corporate Presentation with Noble Capital Markets

enCore Energy Corp. announced the company will be hosting a corporate presentation, followed by a Q & A session moderated by Michael Heim, Noble Capital Market’s senior research analyst

Research, News & Market Data on enCore Energy

Watch recent presentation from enCore Energy



Aurania Reports Progress in Drilling Kuri-Yawi Target in Ecuador

Aurania Resources announced that diamond drilling of the Kuri-Yawi target is well underway and proceeding as planned in the Company’s Lost Cities – Cutucu Project in southeastern Ecuador

Research, News & Market Data on Aurania Resources

Watch recent presentation from NobleCon17



Endeavour Silver Closes Sale of El Cubo Mine to VanGold Mining

Endeavour Silver announced that it has now closed the sale of the El Cubo Mine in Guanajuato, Mexico to VanGold Mining Corp

Research, News & Market Data on Endeavour Silver

Watch recent presentation from NobleCon17



Genprex Collaborators Report Positive Preclinical Data for REQORSA™ Immunogene Therapy

Genprex, Inc. announced that its collaborators presented positive preclinical data for the combination of TUSC2 immunogene therapy in combination with chemotherapy and immunotherapies for the treatment of non-small cell lung cancer

Research, News & Market Data on Genprex

Watch recent presentation from NobleCon17



Capstone Turbine Reports Certain Preliminary Unaudited 4th Quarter Results

Capstone Turbine announced its unaudited preliminary financial results for the fourth quarter ended March 31, 2021

Research, News & Market Data on Capstone Turbine

Watch recent presentation from Capstone Turbine

Stay up to date. Follow us:

enCore Energy Corp (ENCUF)(EU:CA) – Invitation to Noble Capital Markets Presentation


enCore Energy Corp.: Invitation to Noble Capital Markets Presentation

 

April 12, 2021 – Vancouver, B.C. – enCore Energy Corp. (TSXV: EU; OTCQB:ENCUF) (the “Company”) is pleased to announce the company will be hosting a corporate presentation, followed by a Q & A session moderated by Michael Heim, Noble Capital Market’s senior research analyst, featuring questions taken from the audience. Registration is free and open to all shareholders and interested parties.

William M. Sheriff,  Executive Chairman & Paul Goranson, CEO will be presenting on Tuesday, April 13th at 1:00 PM EDT. For more information and/or to register for the presentation please visit: Register for the Road Show.

We look forward to seeing you there.

 

About enCore Energy Corp.

enCore Energy Corp. is a U.S. domestic uranium developer focused on becoming a leading in-situ recovery (ISR) uranium producer. The Company is led by a team of industry experts with extensive knowledge and experience in the development and operations of in situ recovery uranium operations. enCore Energy’s opportunities are created from the Company’s transformational acquisition of its two South Texas production facilities, the changing global uranium supply/demand outlook and opportunities for industry consolidation.  These short-term opportunities are augmented by our strong long-term commitment to working with local indigenous communities in New Mexico where the company holds significant uranium resources.

 

For additional information:
William M. Sheriff
Executive Chairman
972-333-2214
info@encoreenergycorp.com
www.encoreenergycorp.com

Aurania Resources Ltd. (AUIAF)(ARU:CA) – Reports High-Grade Silver-Zinc from Outcrop at Tiria-Shimpia

 


Aurania Reports High-Grade Silver-Zinc from Outcrop at Tiria-Shimpia

 

Toronto, Ontario, April 12, 2021 – Aurania Resources Ltd. (TSXV: ARU) (OTCQB: AUIAF) (Frankfurt: 20Q) (“Aurania” or the “Company”) reports on its first channel rock-chip sampling from the Tiria-Shimpia silver-zinc zone – a target that is over 15 kilometres (“km”) in length, in the central part of the Company’s Lost Cities – Cutucu Project (“Project”) in southeastern Ecuador.    

Seven mineralized layers have been identified, one of which is 50 metres (“m”) thick.  So far, the layers have been traced laterally, through intermittent exposures in thick jungle, for between 500m and 1,100m.  As can be appreciated, with mineralization of this magnitude it will be some time before the full surface extent is truly known and sampled, however the Company is already making plans to diamond drill several key exposures in the near term.   

Aurania’s Chairman & CEO, Dr. Keith Barron commented, “Shareholders will be aware that we have been working on Tiria-Shimpia for some time now.  Earliest indications were that we could be dealing with a simple vein system of limited mineral volume.  We are now very much aware that we are dealing with a different beast: we have traced it along trend for over 15 kilometres, and we’re starting to demonstrate continuity between one exposure and the next, Tiria-Shimpia is shaping up to be Aurania’s first discovery.  While this target is evolving, we are running our concurrent drill programs at Tsenken N1 and Kuri-Yawi, both of which give us exposure to making additional discoveries.  The Tiria-Shimpia target now extends across almost the entire width of our concession block as illustrated in Figure 1.  Our regional exploration teams are finding further extensions to the mineralized system, and our expectation is that it will grow further.”  

Additional soil sampling has expanded the area in which silver and zinc have been found in the Tiria-Shimpia target area by approximately 120% since soil results were last reported in the press release dated February 8, 2021.  

 

Figure 1. Plan view of Tiria-Shimpia target area showing its central location in the Lost Cities – Cutucu concession area.  Footprint of silver in soil shown.

 

Concurrent rock-chip sampling has confirmed that the target contains high-grade mineralization, and the next logical step is to demonstrate continuity of the mineralization by channel sampling outcrops where the bedrock is exposed at surface on the jungle floor.  Channel sampling, in which a chisel is used to extract chips of rock from a 10 centimetre (4 inch) wide track over the mineralized rock, provides a representative sample of grade over the width of the observed mineralization.

Mineralization has so far been found in seven layers of limestone and dolomite that are interlayered with sandstone.  Highlights, shown in Figure 2, are:

•    Unit P: mineralization has been observed over a true thickness of approximately 50m and extends at least 1km along trend.  Intensely mineralized layers within the dolomite were channel sampled, returning grades of 2m at 12g/t silver and 3.9% zinc and 0.8m of 26g/t silver and 6.4% zinc.
•    Unit H: has been sampled in two channel samples spaced 500m apart along its length of 1km, that returned grades of 4m at 21g/t silver and 9.3% zinc, and 1m at 8g/t silver and 4.8% zinc. 
•    Unit J: has been traced 900m along trend with the one channel sample taken, returning a grade of 48g/t silver and 39.6% zinc.
•    Unit N: has been traced 1.1km along trend and a grab sample from outcrop had a grade of 199g/t silver with 22% zinc and 13% lead (see press release dated September 25, 2020).

 

Figure 2.  a. Plan view of silver distribution in soil at Tiria-Shimpia.  This shows where the mineralized layers or sheets come to surface along the edge of the mountains.  b. Provides detail of part of the system. The brown lines show where the mineralized layers come to surface.  These sheets extend westwards (to the left) under the mountain.  The tables show the silver and zinc grades of samples, the location of which is shown in b.  The samples for which a sample length is given are channel samples.  

 

Scout Drilling
•    Tiria-Shimpia: Some drill sites have already been selected and others will be based on the distribution of grade in the mineralized sheets as defined by the channel sampling, which will be done as systematically as the scattered outcrop allows.   While this detailed sampling is being done, other exploration teams are sampling soil to identify further areas of metal enrichment and others are exploring adjacent areas for possible further extensions to the Tiria-Shimpia mineralized system.  
•    Tsenken N1: The first drill hole at Tsenken N1 has been completed to a depth of 722 meters and assay results are awaited.
•    Kuri-Yawi: Drilling at Kuri-Yawi is underway with a second rig that can drill to approximately 1,200 metres.

Geological Details of the Area Sampled at Tiria-Shimpia
Mineralization is massive sphalerite and galena, occurring with strontian barite and pyrite/marcasite in dolomitic strata.  The exposures have been leached and weathered, which is identified by radiating masses of cerussite (lead carbonate) on the surface of outcrops.  Therefore, assay results from initial rock-chip sampling may understate underlying metal content.  Several MobileMT lines were run over the zones during the airborne geophysical survey and anomalies appear to be correlated with surface exposures of mineralized layers.

The channel sample results reported in this press release are in the north-central part of the Tiria-Shimpia target area (Figure 2a).  Units F and H, the uppermost mineralized layers, lie at the contact between sandstone and dolomite, and units J, K, L and N are mineralized dolomite layers within sandstone.  

 

Figure 3.  Field teams measuring the true width of mineralized layers exposed in the bank of a stream.

 

Figure 4.  Massive sphalerite (fine-grained, brown) and galena (gray metallic) from the core of one of the high-grade layers of mineralization at Tiria-Shimpia.

 

Figure 5.  Left:  Galena with radiating masses of cerussite.  Right:  Clots of galena within barite-celestite.

 

Sample Analysis & Quality Assurance / Quality Control (“QAQC”) 
Laboratories: The soil samples were prepared for analysis at MS Analytical (“MSA”) in Cuenca, Ecuador, and the analyses were done in Vancouver, Canada. 
Sample preparation: The rock samples were jaw-crushed to 10 mesh (crushed material passes through a mesh with apertures of 2 millimetres (“mm”)), from which a one-kilogram sub-sample was taken.  The sub-sample was crushed to a grain size of 0.075mm and a 200 gram (“g”) split was set aside for analysis.   
Analytical procedure:  Approximately 0.25g of rock pulp underwent four-acid digestion and analysis for 48 elements by ICP-MS.  For the over-limit samples, those that had a grade of greater than 1% zinc and lead, and 100g/t silver, 0.4 grams of pulp underwent digestion in four acids and the resulting liquid was diluted and analyzed by ICP-MS.     
QAQC: Aurania personnel inserted a certified standard pulp sample, alternating with a field blank, at approximate 20 sample intervals in all sample batches. Aurania’s analysis of results from its independent QAQC samples showed the batches reported on above, lie within acceptable limits.  In addition, the labs reported that the analyses had passed their internal QAQC tests. 

Qualified Person
The geological information contained in this news release has been verified and approved by Jean-Paul Pallier, MSc.  Mr. Pallier is a designated EurGeol by the European Federation of Geologists and a Qualified Person as defined by National Instrument 43-101, Standards of Disclosure for Mineral Projects of the Canadian Securities Administrators.

About Aurania
Aurania is a mineral exploration company engaged in the identification, evaluation, acquisition and exploration of mineral property interests, with a focus on precious metals and copper in South America.  Its flagship asset, The Lost Cities – Cutucu Project, is located in the Jurassic Metallogenic Belt in the eastern foothills of the Andes mountain range of southeastern Ecuador.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. 

Forward-Looking Statements
This news release may contain forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurania. Forward-looking statements include estimates and statements that describe Aurania’s future plans, objectives or goals, including words to the effect that Aurania or its management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as “believes”, “anticipates”, “expects”, “estimates”, “may”, “could”, “would”, “will”, or “plan”. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to Aurania, Aurania provides no assurance that actual results will meet management’s expectations. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward looking information in this news release includes, but is not limited to Aurania’s objectives, goals or future plans, statements, exploration results, potential mineralization, the corporation’s portfolio, treasury, management team and enhanced capital markets profile, the estimation of mineral resources, exploration, timing of the commencement of operations and estimates of market conditions. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, failure to identify mineral resources, failure to convert estimated mineral resources to reserves, the inability to complete a feasibility study which recommends a production decision, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, regulatory, environmental or other project approvals, political risks, inability to fulfill the duty to accommodate indigenous peoples, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, changes in exchange rates, fluctuations in commodity prices, delays in the development of projects, capital and operating costs varying significantly from estimates and the other risks involved in the mineral exploration and development industry, the effects of COVID-19 on the business of the Company including but not limited to the effects of COVID-19 on the price of commodities, capital market conditions, restrictions on labour and international travel and supply chains, and those risks set out in Aurania’s public documents filed on SEDAR. Although Aurania believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Aurania disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

Endeavor Silver (EXK) – Closes Sale of El Cubo Mine to VanGold Mining

 


Endeavour Silver Closes Sale of El Cubo Mine to VanGold Mining

 

VANCOUVER, British Columbia, April 12, 2021 (GLOBE NEWSWIRE) —
Endeavour Silver Corp. (TSX: EDR, NYSE: EXK)
(“Endeavour”) announces that it has now closed the sale of the El Cubo Mine in Guanajuato, Mexico to VanGold Mining Corp. (“VanGold”) for $15 million in cash and share payments plus up to $3 million in future contingent payments (all dollar amounts in US dollars unless otherwise noted) (the “Transaction”).

VanGold paid $15,000,000 to Endeavour as follows:

  • $7.5 million cash on closing.
  • $5.0 million (C$6,399,317.40) in VanGold common shares (“VanGold Shares”) on closing, priced at $0.2344 (C$0.30) per VanGold Share for a total of 21,331,058 VanGold Shares (“Consideration
    Shares
    ”) representing approximately 10.9% of the issued and outstanding VanGold Shares.
  • $2.5 million promissory note due 12 months from closing.

VanGold has also agreed to pay Endeavour up to an additional $3,000,000 in contingent payments based on the following:

  • $1.0 million upon VanGold producing 3,000,000 silver equivalent ounces from the El Cubo mill, derived from either the El Cubo or El Pinguico project, $500,000 of which may, in VanGold’s discretion, be paid in VanGold Shares.
  • $1.0 million if the price of gold closes at or above $2,000 per ounce for 20 consecutive trading days within two years after the closing date of the Transaction.
  • A further $1.0 million if the price of gold closes at or above $2,200 per ounce for 20 consecutive trading days within three years after the closing date of the Transaction.

Bradford Cooke, Endeavour CEO and Director, commented, “We are pleased to close this transaction and I congratulate VanGold for helping make it a win-win deal for both companies. They are in the best position to create more value out of the El Cubo assets given their emerging El Pinguico project located very close to El Cubo, and we now become the largest shareholder of VanGold. I look forward to supporting VanGold in their efforts to become the next junior silver-gold producer in Mexico!”

On the closing of the Transaction, Endeavour acquired 21,331,058 VanGold Shares. Based on 194,931,838 VanGold Shares outstanding as of the closing date of the Transaction, the Consideration Shares represent 10.9% of the outstanding VanGold Shares on an undiluted basis. Prior to the closing date of the Transaction, Endeavour did not own any VanGold Shares or other securities of VanGold.   Endeavour has agreed to abstain from voting its shares of VanGold, other than as recommended by VanGold’s management, for a period of 2 years, and to a 12-month restriction on the resale of any VanGold shares acquired in this Transaction.

Endeavour acquired its interest in the Consideration Shares for long term investment purposes and will continue to monitor the business, prospects, financial condition and potential capital requirements of VanGold. Endeavour may acquire additional securities of VanGold including on the open market or through private acquisitions or sell securities of VanGold including on the open market or through private dispositions in the future depending on market conditions, reformulation of plans and/or other relevant factors.

About Endeavour Silver – Endeavour Silver Corp. is a mid-tier precious metals mining company that owns and operates three high-grade, underground, silver-gold mines in Mexico. Endeavour is currently advancing the Terronera mine project towards a development decision and exploring its portfolio of exploration and development projects in Mexico and Chile to facilitate its goal to become a premier senior silver producer.  Our philosophy of corporate social integrity creates value for all stakeholders.

SOURCE Endeavour Silver Corp.

Endeavour will file an early warning report in connection with the Transaction on SEDAR at www.sedar.com. A copy of the report may be obtained by contacting Galina Meleger at:  

Contact Information
Galina Meleger, Director Investor Relations
Toll free: (877) 685-9775
Tel: (604) 640-4804
Email: gmeleger@edrsilver.com
Website: www.edrsilver.com

Follow Endeavour Silver on Facebook, Twitter, Instagram and LinkedIn

Cautionary Note Regarding Forward-Looking Statements

This
news release contains “forward-looking statements” within the meaning of the
United States private securities litigation reform act of 1995 and
“forward-looking information” within the meaning of applicable Canadian
securities legislation. Such forward-looking statements and information herein
include but are not limited to statements regarding future prospects of the El
Cubo and El Pinguico projects and future acquisitions or dispositions of
VanGold Shares. The Company does not intend to and does not assume any obligation
to update such forward-looking statements or information, other than as
required by applicable law. 

Forward-looking
statements or information involve known and unknown risks, uncertainties and
other factors that may cause the actual results, level of activity, production
levels, performance or achievements to be materially different from those
expressed or implied by such statements. Such factors include but are not
limited to the ultimate impact of the COVID 19 pandemic on operations and
results, changes in production and costs guidance, national and local
governments, legislation, taxation, controls, regulations and political or
economic developments in Canada and Mexico; financial risks due to precious
metals prices, operating or technical difficulties in mineral exploration,
development and mining activities; risks and hazards of mineral exploration, development
and mining; the speculative nature of mineral exploration and development and
risks in obtaining necessary licenses and permits,

Forward-looking
statements are based on assumptions management believes to be reasonable,
including but not limited to: the continued exploration and mining operations,
no material adverse change in the market price of commodities, mining
operations will operate and the mining products will be completed in accordance
with management’s expectations and achieve their stated production outcomes,
and such other assumptions and factors as set out herein. Although the Company
has attempted to identify important factors that could cause actual results to
differ materially from those contained in forward-looking statements or information,
there may be other factors that cause results to be materially different from
those anticipated, described, estimated, assessed or intended. There can be no
assurance that any forward-looking statements or information will prove to be
accurate as actual results and future events could differ materially from those
anticipated in such statements or information. Accordingly, readers should not
place undue reliance on forward-looking statements or information. 
 

Source: Endeavour Silver Corporation

Genprex (GNPX) – Collaborators Report Positive Preclinical Data for REQORSA Immunogene Therapy


Genprex Collaborators Report Positive Preclinical Data for REQORSA™ Immunogene Therapy in Non-Small Cell Lung Cancer at the 2021 AACR Annual Meeting

 

REQORSA Enhances Efficacy of Chemo-Immune Combination Therapy in KRAS-LKB1 Mutant NSCLC in Humanized Mice  

REQORSA Overcomes Resistance to Targeted Therapy Osimertinib 

AUSTIN, Texas — (April 12, 2021) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its collaborators presented positive preclinical data for the combination of TUSC2 immunogene therapy (REQORSA™) in combination with chemotherapy and immunotherapies for the treatment of non-small cell lung cancer (NSCLC). Collaborators also presented positive preclinical data for the use of REQORSA in combination with targeted therapies for the treatment of NSCLC. These data were presented in two presentations at the 2021 American Association of Cancer Research (AACR) annual meeting. The TUSC2 gene is a tumor suppressor gene and is the active agent in REQORSA.

“We are pleased to have these positive data that provide further support for the therapeutic potential of REQORSA in combination with immunotherapies and targeted therapies in NSCLC presented before an audience of the world’s leading cancer researchers. These data are particularly encouraging as we look to initiate our upcoming combination Acclaim-1 and Acclaim-2 clinical trials of REQORSA in NSCLC,” said Rodney Varner, President and Chief Executive Officer of Genprex. “We know that many patients inevitably develop resistance to immune checkpoint blockade therapy or EGFR-TKI therapy. These data show that REQORSA in combination with immunotherapies and targeted therapies may provide enhanced efficacy in NSCLC that has become resistant to these regimens, offering hope to a large patient population who currently has limited treatment options.”

Featured Genprex-supported posters presented at AACR 21 include: 

Oral Presentation:

Session: MS.IM02.02 – Overcoming Resistance in the Tumor Microenvironment: Novel Immunomodulatory Agents

Title: “TUSC2 immunogene therapy enhances efficacy of chemo-immune combination therapy and induces robust antitumor immunity in KRAS-LKB1 mutant NSCLC in humanized mice”

Poster Number/Channel: #76/Channel 03

Presentation Date/Time: April 10, 2021 from 2:50-3:00 p.m. ET

Presenters: Ismail M. Meraz, Mourad Majidi, RuPing Shao, Feng Meng, Min Jin Ha, Elizabeth Shpall, Jack A. Roth. University of Texas MD Anderson Cancer Center, Houston, TX

Poster Presentation:

Session: PO.ET03.01 – Drug Resistance in Molecular Targeted Therapies

Title: “Overcoming resistance to osimertinib by TUSC2 gene therapy in EGFR mutant NSCLC”

Poster Number: #1105

Presentation Date/Time: April 10, 2021 from 8:30 a.m. – 11:59 p.m. ET

Presenters: Ismail M. Meraz, Mourad Majidi, RuPing Shao, Lihui Gao, Meng Feng, Huiqin Chen, Min Jin Ha, Jack A Roth

The first presentation, entitled “TUSC2 immunogene therapy enhances efficacy of chemo-immune combination therapy and induces robust antitumor immunity in KRAS-LKB1 mutant NSCLC in humanized mice,” showed that the triple combination of chemotherapy, immunotherapy (immune checkpoint blockade) and REQORSA demonstrated strong antitumor efficacy and induced robust antitumor immunity in KRAS-LKB1 (KL)-mutant NSCLC in clinically relevant humanized mice models.

In this study, researchers evaluated the antitumor immune response of a chemo-immunotherapy combination with REQORSA on highly metastatic KL-mutant human lung cancer in humanized mice. Humanized mice were first treated with REQORSA, immunotherapy nivolumab (Opdivo®), or the combination. The results showed synergistic antitumor activity with the combination. Next, humanized mice were treated with REQORSA, immunotherapy pembrolizumab (Keytruda®), or the combination. When REQORSA was added to the chemotherapy and immune checkpoint blockade combination, metastases regression was significantly greater than either REQORSA, REQORSA and pembrolizumab, or chemotherapy and pembrolizumab treatments.

“KRAS is a frequent genomic driver in lung adenocarcinoma,”, said Michael Redman, Executive Vice President and Chief Operating Officer of Genprex. “LKB1 (also known as STK11) is a distinct subgroup of KRAS-mutants and is the most prevalent genomic driver of resistance to PD-1 blockade in KRAS-mutant lung cancer.”   

The second poster, entitled “Overcoming resistance to osimertinib by TUSC2 gene therapy in EGFR-mutant NSCLC,” showed that REQORSA in combination with targeted therapy osimertinib (Tagrisso®) demonstrated synergistic antitumor efficacy in EGFR mutant osimertinib resistant NSCLC tumors in H1975-OsiR isogenic tumors. Researchers also found that the upregulation of PDK1 was associated with osimertinib resistance.

In this study, researchers developed an osimertinib resistant H1975-OsiR isogenic cell line through continuous exposure to osimertinib. Xenograft tumors from both H1975-parental and H1975-OsiR cells were developed in NSG mice and were treated with osimertinib. Synergistic antitumor activity of REQORSA and osimertinib was found in H1975-OsiR tumors. The combinations showed a robust antitumor effect compared with single agent treatment groups. Reverse phase protein array (RPPA) data showed that PDK1 was significantly upregulated in the REQORSA and osimertinib group when compared with either control, osimertinib alone or REQORSA alone treated H1975-OsiR tumors, indicating that PDK1 may be associated with osimertinib resistance. No PDK1 inhibitor effect was found in the REQORSA treated group, implicating the specific role of PDK1 in osimertinib resistance.

These AACR presentations and posters have been made available on Genprex’ website at www.genprex.com.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso®) for patients with EGFR mutations whose tumors progressed after treatment with osimertinib alone.

The Company is preparing to initiate its Acclaim-1 and Acclaim-2 clinical trials for the treatment of NSCLC. Acclaim-1 is an open-label, multi-center Phase 1/2 clinical trial that combines REQORSA with AstraZeneca’s Tagrisso in patients with late-stage NSCLC with mutated epidermal growth factor receptors (EGFRs), whose disease progressed after treatment with Tagrisso. The Acclaim-2 clinical trial will combine REQORSA with Merck & Co’s Keytruda for NSCLC patients who are low expressors (1% to 49%) of the protein programmed death-ligand 1 (PD-L1).For more information, please visit the Company’s web site at www.genprex.com or follow Genprex on TwitterFacebook and LinkedIn.

Cautionary Language Concerning Forward-Looking Statements 

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex’s reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under “Item 1A – Risk Factors” in Genprex’s Annual Report on Form 10-K.

Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the timing and success of Genprex’s clinical trials and regulatory approvals; the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes;  Genprex’s future growth and financial status; Genprex’s commercial and strategic partnerships including the scale up of the manufacture of its product candidates; and Genprex’s intellectual property and licenses. 

These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.

Genprex, Inc.
(877) 774-GNPX (4679)

Investor Relations
GNPX Investor Relations
(877) 774-GNPX (4679) ext. #2
investors@genprex.com

Media Contact
Genprex Media Relations
(877) 774-GNPX (4679) ext. #3
media@genprex.com

 

How PPI Impacts CPI Numbers

 


Consumer Inflation and the Impact of Producer Prices

 

Inflation, its impact on interest rates, the cost of employees, corporate profits, and global competitiveness, is creating more anxiety than it has in decades. Since 2008, economists were more likely to be concerned and debate how to stave off deflation. That fear seems like a distant memory since $6 trillion has been added to the economy over the past year. March’s change in consumer inflation is released this week. The release will give the market a renewed glimpse of how much price appreciation consumers have sustained from shortages and trillions of more dollars chasing the same or fewer goods and services.

One factor that may have already had a big impact on March consumer inflation are the quickly rising producer prices. The Bureau of Labor Statistics reports Producer Price Index (PPI) monthly on the previous month’s data for a few days before the Consumer Price Index (CPI) is released for the same month (PPI was released 4/9. CPI will be reported on 4/13).

PPI’s Warning

Producer prices, as reported Friday, April 9, increased 1%. This is a significant jump. In fact, it is double the rate economists expected and up from 0.5% in February. This sharp rise of costs to produce and the reported success in passing the higher wholesale costs on to consumers and small business owners indicates it will work its way into final CPI numbers in short order.

Comparing the increase to March of last year, the PPI jumped by 4.2%, this was the sharpest year-over-year increase since 2011, according to the BLS.

Producer Price Index, Month Over Month Change

 

Next month’s release of both PPI and CPI are more than likely to show dramatic YOY increases. Much of this can be discounted as inflation during April last year plunged by 1.1% in response to new lockdown orders. This low inflation month is the basis for one-year measurement. The name for this distortion is the “base effect,” and investors should be aware of it before they are startled by what looks to be rampant inflation without the context of what happened last April distorting the YOY measure.

We can see from the BLS chart below that PPI hit a high in January 2020 with an index value of 119.2. In February and March last year, it dropped 0.5% from the prior month, and in April, it plunged 1.1% to an index value of 116.7, partly driven by the collapse in fuel prices. It has been rising ever since.

 

Source: U.S. Bureau of Labor Statistics

 

Looking Forward

What might April prices look like? The most recent index value is 123.1, which is 5.5% higher than April 2020. If the PPI rises 0.5% this month (April) from 123.1, it adds up to a 6% year-over-year increase. This would be the highest since November 2009, when the U.S. economy was awakening from the financial crisis. After April’s data, the issue with base measurement will have already been taken into account, leaving May’s numbers (reported in June) as a fresh start without basis problems.

 

 

Take-Away

Inflation pressures are giving way to higher prices in the manufacturing and services pipeline. The producer price index is showing significant increases even when netting out the base effect. Companies are reporting they are successfully passing these costs on to the consumer.  This means higher CPI down the road, which will lead to greater challenges for the Fed to fulfill its commitment to low rates through next year.

 

Suggested Reading on Channelchek:

Winners and Losers in the American Job Plan

IRA Investments and Small-Cap Stocks



Are Inflation and Interest Rates Expected to Rise

$1.9 Trillion in Terms We Can Better Relate to

 

Sources:

 

https://www.bls.gov/news.release/pdf/cpi.pdf

https://www.bls.gov/ppi/

https://www.bls.gov/news.release/ppi.nr0.htm

https://www.markiteconomics.com/Public/Home/PressRelease/6123ab3169954de186a8b7c543eb6035

Stay up to date. Follow us:

           


Stay up to date. Follow us:

Release – Aurania Resources Ltd. (AUIAF)(ARU:CA) – Reports High-Grade Silver-Zinc from Outcrop at Tiria-Shimpia

 


Aurania Reports High-Grade Silver-Zinc from Outcrop at Tiria-Shimpia

 

Toronto, Ontario, April 12, 2021 – Aurania Resources Ltd. (TSXV: ARU) (OTCQB: AUIAF) (Frankfurt: 20Q) (“Aurania” or the “Company”) reports on its first channel rock-chip sampling from the Tiria-Shimpia silver-zinc zone – a target that is over 15 kilometres (“km”) in length, in the central part of the Company’s Lost Cities – Cutucu Project (“Project”) in southeastern Ecuador.    

Seven mineralized layers have been identified, one of which is 50 metres (“m”) thick.  So far, the layers have been traced laterally, through intermittent exposures in thick jungle, for between 500m and 1,100m.  As can be appreciated, with mineralization of this magnitude it will be some time before the full surface extent is truly known and sampled, however the Company is already making plans to diamond drill several key exposures in the near term.   

Aurania’s Chairman & CEO, Dr. Keith Barron commented, “Shareholders will be aware that we have been working on Tiria-Shimpia for some time now.  Earliest indications were that we could be dealing with a simple vein system of limited mineral volume.  We are now very much aware that we are dealing with a different beast: we have traced it along trend for over 15 kilometres, and we’re starting to demonstrate continuity between one exposure and the next, Tiria-Shimpia is shaping up to be Aurania’s first discovery.  While this target is evolving, we are running our concurrent drill programs at Tsenken N1 and Kuri-Yawi, both of which give us exposure to making additional discoveries.  The Tiria-Shimpia target now extends across almost the entire width of our concession block as illustrated in Figure 1.  Our regional exploration teams are finding further extensions to the mineralized system, and our expectation is that it will grow further.”  

Additional soil sampling has expanded the area in which silver and zinc have been found in the Tiria-Shimpia target area by approximately 120% since soil results were last reported in the press release dated February 8, 2021.  

 

Figure 1. Plan view of Tiria-Shimpia target area showing its central location in the Lost Cities – Cutucu concession area.  Footprint of silver in soil shown.

 

Concurrent rock-chip sampling has confirmed that the target contains high-grade mineralization, and the next logical step is to demonstrate continuity of the mineralization by channel sampling outcrops where the bedrock is exposed at surface on the jungle floor.  Channel sampling, in which a chisel is used to extract chips of rock from a 10 centimetre (4 inch) wide track over the mineralized rock, provides a representative sample of grade over the width of the observed mineralization.

Mineralization has so far been found in seven layers of limestone and dolomite that are interlayered with sandstone.  Highlights, shown in Figure 2, are:

•    Unit P: mineralization has been observed over a true thickness of approximately 50m and extends at least 1km along trend.  Intensely mineralized layers within the dolomite were channel sampled, returning grades of 2m at 12g/t silver and 3.9% zinc and 0.8m of 26g/t silver and 6.4% zinc.
•    Unit H: has been sampled in two channel samples spaced 500m apart along its length of 1km, that returned grades of 4m at 21g/t silver and 9.3% zinc, and 1m at 8g/t silver and 4.8% zinc. 
•    Unit J: has been traced 900m along trend with the one channel sample taken, returning a grade of 48g/t silver and 39.6% zinc.
•    Unit N: has been traced 1.1km along trend and a grab sample from outcrop had a grade of 199g/t silver with 22% zinc and 13% lead (see press release dated September 25, 2020).

 

Figure 2.  a. Plan view of silver distribution in soil at Tiria-Shimpia.  This shows where the mineralized layers or sheets come to surface along the edge of the mountains.  b. Provides detail of part of the system. The brown lines show where the mineralized layers come to surface.  These sheets extend westwards (to the left) under the mountain.  The tables show the silver and zinc grades of samples, the location of which is shown in b.  The samples for which a sample length is given are channel samples.  

 

Scout Drilling
•    Tiria-Shimpia: Some drill sites have already been selected and others will be based on the distribution of grade in the mineralized sheets as defined by the channel sampling, which will be done as systematically as the scattered outcrop allows.   While this detailed sampling is being done, other exploration teams are sampling soil to identify further areas of metal enrichment and others are exploring adjacent areas for possible further extensions to the Tiria-Shimpia mineralized system.  
•    Tsenken N1: The first drill hole at Tsenken N1 has been completed to a depth of 722 meters and assay results are awaited.
•    Kuri-Yawi: Drilling at Kuri-Yawi is underway with a second rig that can drill to approximately 1,200 metres.

Geological Details of the Area Sampled at Tiria-Shimpia
Mineralization is massive sphalerite and galena, occurring with strontian barite and pyrite/marcasite in dolomitic strata.  The exposures have been leached and weathered, which is identified by radiating masses of cerussite (lead carbonate) on the surface of outcrops.  Therefore, assay results from initial rock-chip sampling may understate underlying metal content.  Several MobileMT lines were run over the zones during the airborne geophysical survey and anomalies appear to be correlated with surface exposures of mineralized layers.

The channel sample results reported in this press release are in the north-central part of the Tiria-Shimpia target area (Figure 2a).  Units F and H, the uppermost mineralized layers, lie at the contact between sandstone and dolomite, and units J, K, L and N are mineralized dolomite layers within sandstone.  

 

Figure 3.  Field teams measuring the true width of mineralized layers exposed in the bank of a stream.

 

Figure 4.  Massive sphalerite (fine-grained, brown) and galena (gray metallic) from the core of one of the high-grade layers of mineralization at Tiria-Shimpia.

 

Figure 5.  Left:  Galena with radiating masses of cerussite.  Right:  Clots of galena within barite-celestite.

 

Sample Analysis & Quality Assurance / Quality Control (“QAQC”) 
Laboratories: The soil samples were prepared for analysis at MS Analytical (“MSA”) in Cuenca, Ecuador, and the analyses were done in Vancouver, Canada. 
Sample preparation: The rock samples were jaw-crushed to 10 mesh (crushed material passes through a mesh with apertures of 2 millimetres (“mm”)), from which a one-kilogram sub-sample was taken.  The sub-sample was crushed to a grain size of 0.075mm and a 200 gram (“g”) split was set aside for analysis.   
Analytical procedure:  Approximately 0.25g of rock pulp underwent four-acid digestion and analysis for 48 elements by ICP-MS.  For the over-limit samples, those that had a grade of greater than 1% zinc and lead, and 100g/t silver, 0.4 grams of pulp underwent digestion in four acids and the resulting liquid was diluted and analyzed by ICP-MS.     
QAQC: Aurania personnel inserted a certified standard pulp sample, alternating with a field blank, at approximate 20 sample intervals in all sample batches. Aurania’s analysis of results from its independent QAQC samples showed the batches reported on above, lie within acceptable limits.  In addition, the labs reported that the analyses had passed their internal QAQC tests. 

Qualified Person
The geological information contained in this news release has been verified and approved by Jean-Paul Pallier, MSc.  Mr. Pallier is a designated EurGeol by the European Federation of Geologists and a Qualified Person as defined by National Instrument 43-101, Standards of Disclosure for Mineral Projects of the Canadian Securities Administrators.

About Aurania
Aurania is a mineral exploration company engaged in the identification, evaluation, acquisition and exploration of mineral property interests, with a focus on precious metals and copper in South America.  Its flagship asset, The Lost Cities – Cutucu Project, is located in the Jurassic Metallogenic Belt in the eastern foothills of the Andes mountain range of southeastern Ecuador.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. 

Forward-Looking Statements
This news release may contain forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurania. Forward-looking statements include estimates and statements that describe Aurania’s future plans, objectives or goals, including words to the effect that Aurania or its management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as “believes”, “anticipates”, “expects”, “estimates”, “may”, “could”, “would”, “will”, or “plan”. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to Aurania, Aurania provides no assurance that actual results will meet management’s expectations. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward looking information in this news release includes, but is not limited to Aurania’s objectives, goals or future plans, statements, exploration results, potential mineralization, the corporation’s portfolio, treasury, management team and enhanced capital markets profile, the estimation of mineral resources, exploration, timing of the commencement of operations and estimates of market conditions. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, failure to identify mineral resources, failure to convert estimated mineral resources to reserves, the inability to complete a feasibility study which recommends a production decision, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, regulatory, environmental or other project approvals, political risks, inability to fulfill the duty to accommodate indigenous peoples, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, changes in exchange rates, fluctuations in commodity prices, delays in the development of projects, capital and operating costs varying significantly from estimates and the other risks involved in the mineral exploration and development industry, the effects of COVID-19 on the business of the Company including but not limited to the effects of COVID-19 on the price of commodities, capital market conditions, restrictions on labour and international travel and supply chains, and those risks set out in Aurania’s public documents filed on SEDAR. Although Aurania believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Aurania disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

Release – Endeavor Silver (EXK) – Closes Sale of El Cubo Mine to VanGold Mining

 


Endeavour Silver Closes Sale of El Cubo Mine to VanGold Mining

 

VANCOUVER, British Columbia, April 12, 2021 (GLOBE NEWSWIRE) —
Endeavour Silver Corp. (TSX: EDR, NYSE: EXK)
(“Endeavour”) announces that it has now closed the sale of the El Cubo Mine in Guanajuato, Mexico to VanGold Mining Corp. (“VanGold”) for $15 million in cash and share payments plus up to $3 million in future contingent payments (all dollar amounts in US dollars unless otherwise noted) (the “Transaction”).

VanGold paid $15,000,000 to Endeavour as follows:

  • $7.5 million cash on closing.
  • $5.0 million (C$6,399,317.40) in VanGold common shares (“VanGold Shares”) on closing, priced at $0.2344 (C$0.30) per VanGold Share for a total of 21,331,058 VanGold Shares (“Consideration
    Shares
    ”) representing approximately 10.9% of the issued and outstanding VanGold Shares.
  • $2.5 million promissory note due 12 months from closing.

VanGold has also agreed to pay Endeavour up to an additional $3,000,000 in contingent payments based on the following:

  • $1.0 million upon VanGold producing 3,000,000 silver equivalent ounces from the El Cubo mill, derived from either the El Cubo or El Pinguico project, $500,000 of which may, in VanGold’s discretion, be paid in VanGold Shares.
  • $1.0 million if the price of gold closes at or above $2,000 per ounce for 20 consecutive trading days within two years after the closing date of the Transaction.
  • A further $1.0 million if the price of gold closes at or above $2,200 per ounce for 20 consecutive trading days within three years after the closing date of the Transaction.

Bradford Cooke, Endeavour CEO and Director, commented, “We are pleased to close this transaction and I congratulate VanGold for helping make it a win-win deal for both companies. They are in the best position to create more value out of the El Cubo assets given their emerging El Pinguico project located very close to El Cubo, and we now become the largest shareholder of VanGold. I look forward to supporting VanGold in their efforts to become the next junior silver-gold producer in Mexico!”

On the closing of the Transaction, Endeavour acquired 21,331,058 VanGold Shares. Based on 194,931,838 VanGold Shares outstanding as of the closing date of the Transaction, the Consideration Shares represent 10.9% of the outstanding VanGold Shares on an undiluted basis. Prior to the closing date of the Transaction, Endeavour did not own any VanGold Shares or other securities of VanGold.   Endeavour has agreed to abstain from voting its shares of VanGold, other than as recommended by VanGold’s management, for a period of 2 years, and to a 12-month restriction on the resale of any VanGold shares acquired in this Transaction.

Endeavour acquired its interest in the Consideration Shares for long term investment purposes and will continue to monitor the business, prospects, financial condition and potential capital requirements of VanGold. Endeavour may acquire additional securities of VanGold including on the open market or through private acquisitions or sell securities of VanGold including on the open market or through private dispositions in the future depending on market conditions, reformulation of plans and/or other relevant factors.

About Endeavour Silver – Endeavour Silver Corp. is a mid-tier precious metals mining company that owns and operates three high-grade, underground, silver-gold mines in Mexico. Endeavour is currently advancing the Terronera mine project towards a development decision and exploring its portfolio of exploration and development projects in Mexico and Chile to facilitate its goal to become a premier senior silver producer.  Our philosophy of corporate social integrity creates value for all stakeholders.

SOURCE Endeavour Silver Corp.

Endeavour will file an early warning report in connection with the Transaction on SEDAR at www.sedar.com. A copy of the report may be obtained by contacting Galina Meleger at:  

Contact Information
Galina Meleger, Director Investor Relations
Toll free: (877) 685-9775
Tel: (604) 640-4804
Email: gmeleger@edrsilver.com
Website: www.edrsilver.com

Follow Endeavour Silver on Facebook, Twitter, Instagram and LinkedIn

Cautionary Note Regarding Forward-Looking Statements

This
news release contains “forward-looking statements” within the meaning of the
United States private securities litigation reform act of 1995 and
“forward-looking information” within the meaning of applicable Canadian
securities legislation. Such forward-looking statements and information herein
include but are not limited to statements regarding future prospects of the El
Cubo and El Pinguico projects and future acquisitions or dispositions of
VanGold Shares. The Company does not intend to and does not assume any obligation
to update such forward-looking statements or information, other than as
required by applicable law. 

Forward-looking
statements or information involve known and unknown risks, uncertainties and
other factors that may cause the actual results, level of activity, production
levels, performance or achievements to be materially different from those
expressed or implied by such statements. Such factors include but are not
limited to the ultimate impact of the COVID 19 pandemic on operations and
results, changes in production and costs guidance, national and local
governments, legislation, taxation, controls, regulations and political or
economic developments in Canada and Mexico; financial risks due to precious
metals prices, operating or technical difficulties in mineral exploration,
development and mining activities; risks and hazards of mineral exploration, development
and mining; the speculative nature of mineral exploration and development and
risks in obtaining necessary licenses and permits,

Forward-looking
statements are based on assumptions management believes to be reasonable,
including but not limited to: the continued exploration and mining operations,
no material adverse change in the market price of commodities, mining
operations will operate and the mining products will be completed in accordance
with management’s expectations and achieve their stated production outcomes,
and such other assumptions and factors as set out herein. Although the Company
has attempted to identify important factors that could cause actual results to
differ materially from those contained in forward-looking statements or information,
there may be other factors that cause results to be materially different from
those anticipated, described, estimated, assessed or intended. There can be no
assurance that any forward-looking statements or information will prove to be
accurate as actual results and future events could differ materially from those
anticipated in such statements or information. Accordingly, readers should not
place undue reliance on forward-looking statements or information. 
 

Source: Endeavour Silver Corporation

Release – Genprex (GNPX) – Collaborators Report Positive Preclinical Data for REQORSA Immunogene Therapy


Genprex Collaborators Report Positive Preclinical Data for REQORSA™ Immunogene Therapy in Non-Small Cell Lung Cancer at the 2021 AACR Annual Meeting

 

REQORSA Enhances Efficacy of Chemo-Immune Combination Therapy in KRAS-LKB1 Mutant NSCLC in Humanized Mice  

REQORSA Overcomes Resistance to Targeted Therapy Osimertinib 

AUSTIN, Texas — (April 12, 2021) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its collaborators presented positive preclinical data for the combination of TUSC2 immunogene therapy (REQORSA™) in combination with chemotherapy and immunotherapies for the treatment of non-small cell lung cancer (NSCLC). Collaborators also presented positive preclinical data for the use of REQORSA in combination with targeted therapies for the treatment of NSCLC. These data were presented in two presentations at the 2021 American Association of Cancer Research (AACR) annual meeting. The TUSC2 gene is a tumor suppressor gene and is the active agent in REQORSA.

“We are pleased to have these positive data that provide further support for the therapeutic potential of REQORSA in combination with immunotherapies and targeted therapies in NSCLC presented before an audience of the world’s leading cancer researchers. These data are particularly encouraging as we look to initiate our upcoming combination Acclaim-1 and Acclaim-2 clinical trials of REQORSA in NSCLC,” said Rodney Varner, President and Chief Executive Officer of Genprex. “We know that many patients inevitably develop resistance to immune checkpoint blockade therapy or EGFR-TKI therapy. These data show that REQORSA in combination with immunotherapies and targeted therapies may provide enhanced efficacy in NSCLC that has become resistant to these regimens, offering hope to a large patient population who currently has limited treatment options.”

Featured Genprex-supported posters presented at AACR 21 include: 

Oral Presentation:

Session: MS.IM02.02 – Overcoming Resistance in the Tumor Microenvironment: Novel Immunomodulatory Agents

Title: “TUSC2 immunogene therapy enhances efficacy of chemo-immune combination therapy and induces robust antitumor immunity in KRAS-LKB1 mutant NSCLC in humanized mice”

Poster Number/Channel: #76/Channel 03

Presentation Date/Time: April 10, 2021 from 2:50-3:00 p.m. ET

Presenters: Ismail M. Meraz, Mourad Majidi, RuPing Shao, Feng Meng, Min Jin Ha, Elizabeth Shpall, Jack A. Roth. University of Texas MD Anderson Cancer Center, Houston, TX

Poster Presentation:

Session: PO.ET03.01 – Drug Resistance in Molecular Targeted Therapies

Title: “Overcoming resistance to osimertinib by TUSC2 gene therapy in EGFR mutant NSCLC”

Poster Number: #1105

Presentation Date/Time: April 10, 2021 from 8:30 a.m. – 11:59 p.m. ET

Presenters: Ismail M. Meraz, Mourad Majidi, RuPing Shao, Lihui Gao, Meng Feng, Huiqin Chen, Min Jin Ha, Jack A Roth

The first presentation, entitled “TUSC2 immunogene therapy enhances efficacy of chemo-immune combination therapy and induces robust antitumor immunity in KRAS-LKB1 mutant NSCLC in humanized mice,” showed that the triple combination of chemotherapy, immunotherapy (immune checkpoint blockade) and REQORSA demonstrated strong antitumor efficacy and induced robust antitumor immunity in KRAS-LKB1 (KL)-mutant NSCLC in clinically relevant humanized mice models.

In this study, researchers evaluated the antitumor immune response of a chemo-immunotherapy combination with REQORSA on highly metastatic KL-mutant human lung cancer in humanized mice. Humanized mice were first treated with REQORSA, immunotherapy nivolumab (Opdivo®), or the combination. The results showed synergistic antitumor activity with the combination. Next, humanized mice were treated with REQORSA, immunotherapy pembrolizumab (Keytruda®), or the combination. When REQORSA was added to the chemotherapy and immune checkpoint blockade combination, metastases regression was significantly greater than either REQORSA, REQORSA and pembrolizumab, or chemotherapy and pembrolizumab treatments.

“KRAS is a frequent genomic driver in lung adenocarcinoma,”, said Michael Redman, Executive Vice President and Chief Operating Officer of Genprex. “LKB1 (also known as STK11) is a distinct subgroup of KRAS-mutants and is the most prevalent genomic driver of resistance to PD-1 blockade in KRAS-mutant lung cancer.”   

The second poster, entitled “Overcoming resistance to osimertinib by TUSC2 gene therapy in EGFR-mutant NSCLC,” showed that REQORSA in combination with targeted therapy osimertinib (Tagrisso®) demonstrated synergistic antitumor efficacy in EGFR mutant osimertinib resistant NSCLC tumors in H1975-OsiR isogenic tumors. Researchers also found that the upregulation of PDK1 was associated with osimertinib resistance.

In this study, researchers developed an osimertinib resistant H1975-OsiR isogenic cell line through continuous exposure to osimertinib. Xenograft tumors from both H1975-parental and H1975-OsiR cells were developed in NSG mice and were treated with osimertinib. Synergistic antitumor activity of REQORSA and osimertinib was found in H1975-OsiR tumors. The combinations showed a robust antitumor effect compared with single agent treatment groups. Reverse phase protein array (RPPA) data showed that PDK1 was significantly upregulated in the REQORSA and osimertinib group when compared with either control, osimertinib alone or REQORSA alone treated H1975-OsiR tumors, indicating that PDK1 may be associated with osimertinib resistance. No PDK1 inhibitor effect was found in the REQORSA treated group, implicating the specific role of PDK1 in osimertinib resistance.

These AACR presentations and posters have been made available on Genprex’ website at www.genprex.com.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso®) for patients with EGFR mutations whose tumors progressed after treatment with osimertinib alone.

The Company is preparing to initiate its Acclaim-1 and Acclaim-2 clinical trials for the treatment of NSCLC. Acclaim-1 is an open-label, multi-center Phase 1/2 clinical trial that combines REQORSA with AstraZeneca’s Tagrisso in patients with late-stage NSCLC with mutated epidermal growth factor receptors (EGFRs), whose disease progressed after treatment with Tagrisso. The Acclaim-2 clinical trial will combine REQORSA with Merck & Co’s Keytruda for NSCLC patients who are low expressors (1% to 49%) of the protein programmed death-ligand 1 (PD-L1).For more information, please visit the Company’s web site at www.genprex.com or follow Genprex on TwitterFacebook and LinkedIn.

Cautionary Language Concerning Forward-Looking Statements 

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex’s reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under “Item 1A – Risk Factors” in Genprex’s Annual Report on Form 10-K.

Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the timing and success of Genprex’s clinical trials and regulatory approvals; the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes;  Genprex’s future growth and financial status; Genprex’s commercial and strategic partnerships including the scale up of the manufacture of its product candidates; and Genprex’s intellectual property and licenses. 

These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.

Genprex, Inc.
(877) 774-GNPX (4679)

Investor Relations
GNPX Investor Relations
(877) 774-GNPX (4679) ext. #2
investors@genprex.com

Media Contact
Genprex Media Relations
(877) 774-GNPX (4679) ext. #3
media@genprex.com

 

The GEO Group, Inc. (GEO) – Contract Aging: A Deeper Dive

Monday, April 12, 2021

The GEO Group, Inc. (GEO)
Contract Aging: A Deeper Dive

With over 94,000 beds owned, leased or managed across its business lines and serving over 260,000 people daily, GEO is a leading provider of mission critical real estate to its governmental partners. The Company is the first fully integrated equity REIT specializing in the design, financing, development, and operation of secure facilities, processing centers, and community reentry centers in the U.S., Australia, South Africa, and the U.K.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    A Deeper Dive. We took a deeper dive into GEO’s ability to repay its debt. We believe the Company is positioned to handle its debt under nearly any circumstance. Although the executive orders have increased uncertainty around GEO’s business, we continue to believe, for a number of reasons, that the USMS issues will ultimately be resolved in a manner that the Company can live with. While the loss of the BoP business will hurt, it is not fatal, in our view.

    A Stable Business.  In spite of the year-in and year-out changes to its business, including the loss of customers in the past, GEO generates a remarkably stable level of cash flows. We believe the long-term nature of many of its contracts help isolate the Company from a massive run-off of business in a short period of time …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Orion Group Holdings (ORN) – Tampa Yard Sale Moving Ahead

Monday, April 12, 2021

Orion Group Holdings (ORN)
Tampa Yard Sale Moving Ahead

Orion Group Holdings, based in Houston, Texas, is a specialty construction company within the Marine and Industrial Construction sectors, with operations focused in the continental United States and Caribbean. Revenue is split roughly 50/50 between a Marine Construction segment that provides marine facility, pipeline and structural construction services and a Commercial Concrete segment that provides turnkey concrete services in the light commercial and structural construction markets.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Tampa Yard Sale Moving Forward. The Tampa City Council approved the first reading of the zoning change from heavy industrial to mixed use on the West Tyson property in Tampa that is under contract to be sold. The buyer, a developer, had asked for a continuance at the February 11th meeting after one council member expressed concerns about the density of the proposed development plan. The original development plan was scaled back and now includes fewer units (495 versus 649), lower density (26.7 units/acre versus 34.9 units/acre), fewer multi-family buildings (three versus five), and more restaurant/retail space (14k square feet versus 5k square feet). While there were lingering safety concerns about the proximity of the development site to a chlorine plant, the City Council approved the modified plan, with four affirmative votes, two negative votes and one abstentation due to a potential conflict of interest.

    Sale Likely to Close in mid-2Q2021.  The next step to finalize the zoning change is a second reading and adoption, which should happen at the April 22nd City Council meeting. Once that step is completed, the sale should close. Combined with the pending sale of the Port Lavaca property, asset sales could generate more than $25 million and capital allocation should shift from deleveraging to growth …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

CoreCivic, Inc. (CXW) – Contract Aging: A Deeper Dive

Monday, April 12, 2021

CoreCivic, Inc. (CXW)
Contract Aging: A Deeper Dive

CoreCivic is a diversified government solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways. We provide a broad range of solutions to government partners that serve the public good through corrections and detention management, a growing network of residential reentry centers to help address America’s recidivism crisis, and government real estate solutions. We are a publicly traded real estate investment trust and the nation’s largest owner of partnership correctional, detention and residential reentry facilities. We also believe we are the largest private owner of real estate used by U.S. government agencies. The Company has been a flexible and dependable partner for government for more than 35 years. Our employees are driven by a deep sense of service, high standards of professionalism and a responsibility to help government better the public good.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    A Deeper Dive. We took a deeper dive into CoreCivic’s ability to repay its debt. We believe the Company is well positioned to handle its debt under nearly any circumstance. Although the executive orders have increased uncertainty around CoreCivic’s business, we continue to believe, for a number of reasons, that the USMS issues will ultimately be resolved in a manner that the Company can live with.

    A Stable Business.  In spite of the year-in and year-out changes to its business, including the loss of major customers in the past, CoreCivic generates a remarkably stable level of cash flows. We believe the long-term nature of many of its contracts help isolate the Company from a massive run-off of business in a short period of time …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Aurania Resources (AUIAF)(ARU:CA) – Drilling Underway at Kuri-Yawi Target; Recent Financings Enhance Financial Flexibility

Monday, April 12, 2021

Aurania Resources (AUIAF)(ARU:CA)
Drilling Underway at Kuri-Yawi Target; Recent Financings Enhance Financial Flexibility

As of April 24, 2020, Noble Capital Markets research on Aurania Resources is published under ticker symbols (AUIAF and ARU:CA). The price target is in USD and based on ticker symbol AUIAF. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.

Aurania Resources Ltd. is a Canada-based junior mining exploration company engaged in the identification, evaluation, acquisition, and exploration of mineral property interests, with a focus on precious metals and copper. Its flagship asset, The Lost Cities-Cutucu Project, is in southeastern Ecuador in the Province of Morona-Santiago. The company also has several minor projects in Switzerland.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Fully funded for remainder of 2021. Aurania Resources recently completed two financings, including a brokered equity issuance of 2,507,000 common shares for gross proceeds of C$7,771,700 and a private placement of 403,750 common shares for gross proceeds of C$1,250,000. Following the financings, the company had 46,843,388 shares outstanding by our estimate. Based on our forecasted expenditures, the company is fully funded for the remainder of the year.

    Drilling Underway at Kuri-Yawi epithermal target.  Diamond drilling is underway at the Kuri-Yawi target and is testing an epithermal target and a deeper porphyry target down to potentially 1,000 meters. Recall that Aurania’s Mobile MT geophysical survey clearly defined a feature thought to be the sulphide-bearing core of a porphyry at the Yawi target. Epithermal veins were encountered about 100 …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.